Home > Publications database > Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. > print

001     124452
005     20240228145515.0
024 7 _ |a 10.1111/ejh.12888
|2 doi
024 7 _ |a pmid:28370401
|2 pmid
024 7 _ |a 0036-553X
|2 ISSN
024 7 _ |a 0902-4441
|2 ISSN
024 7 _ |a 1600-0609
|2 ISSN
024 7 _ |a altmetric:18724649
|2 altmetric
037 _ _ |a DKFZ-2017-01329
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Baertsch, Marc-Andrea
|0 0000-0002-4000-6904
|b 0
245 _ _ |a Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
260 _ _ |a Oxford
|c 2017
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1509712506_7146
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM).Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m(2) daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG).Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (≥2×10(6) CD34+ cells per kg bw) in 77% (23/30 patients). Patients with prior high-dose melphalan collected a significantly lower median total number of PBSCs than patients without prior high-dose melphalan (3.3×10(6) vs 17×10(6) CD34+ cells/kg bw). Toxicity of HD-CY was frequent with 12 serious adverse events (SAE) in 37% of patients (11/30 patients). Infections accounted for the majority of SAE reports. In two patients, SAEs were lethal (septic shock).These data proof feasibility of PBSC collection at relapse but emphasize the importance of collection and storage of additional PBSC transplants during first-line treatment when mobilization is more efficient and less toxic.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Schlenzka, Jana
|b 1
700 1 _ |a Lisenko, Katharina
|b 2
700 1 _ |a Krzykalla, Julia
|0 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9
|b 3
|u dkfz
700 1 _ |a Becker, Natalia
|0 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0
|b 4
|u dkfz
700 1 _ |a Weisel, Katja
|b 5
700 1 _ |a Noppeney, Richard
|b 6
700 1 _ |a Martin, Hans
|b 7
700 1 _ |a Lindemann, Hans W
|b 8
700 1 _ |a Haenel, Mathias
|b 9
700 1 _ |a Nogai, Axel
|b 10
700 1 _ |a Scheid, Christof
|b 11
700 1 _ |a Salwender, Hans
|b 12
700 1 _ |a Fenk, Roland
|b 13
700 1 _ |a Graeven, Ullrich
|b 14
700 1 _ |a Reimer, Peter
|b 15
700 1 _ |a Schmidt-Hieber, Martin
|b 16
700 1 _ |a Goerner, Martin
|b 17
700 1 _ |a Schmidt-Wolf, Ingo G H
|b 18
700 1 _ |a Klein, Stefan
|b 19
700 1 _ |a Ho, Anthony D
|b 20
700 1 _ |a Goldschmidt, Hartmut
|b 21
700 1 _ |a Wuchter, Patrick
|b 22
773 _ _ |a 10.1111/ejh.12888
|g Vol. 99, no. 1, p. 42 - 50
|0 PERI:(DE-600)2027114-1
|n 1
|p 42 - 50
|t European journal of haematology
|v 99
|y 2017
|x 0902-4441
909 C O |o oai:inrepo02.dkfz.de:124452
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J HAEMATOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21